INM-900 series / InMed Pharma - LARVOL DELTA

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (Yahoo Finance) - "INM-900 - Neurodegenerative Diseases Program: Two cannabinoid analogs are being assessed in in vivo models of neurodegenerative diseases and the Company expects these studies to be completed and a candidate selected for further development in calendar 2Q 2023."

Preclinical • Alzheimer's Disease • CNS Disorders • Huntington's Disease • Parkinson's Disease

InMed Provides Business Update and Milestones for 2023 (GlobeNewswire) - “INM-900 – Developing a new approach in neurodegenerative disease: Our pipeline was expanded this year with the addition of our neurodegenerative disease program. With recent promising preclinical data, InMed plans to expedite its INM-900 program for the potential treatment of neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease. Our research demonstrated the neuroprotective effects of specific cannabinoid analogs and their potential to improve neuronal function. Two cannabinoid analogs are being assessed in in vivo models of neurodegenerative disease. Our approach may target multiple novel disease pathways versus the majority of drugs currently in clinical development for these diseases.”

New trial • Preclinical • Alzheimer's Disease • CNS Disorders • Huntington's Disease • Parkinson's Disease